[
  {
    "symbol": "IMGN",
    "price": 18.89,
    "beta": 0.891197,
    "volAvg": 8042898,
    "mktCap": 4835273300,
    "lastDiv": 0,
    "range": "3.61-20.29",
    "changes": -0.19,
    "companyName": "ImmunoGen, Inc.",
    "currency": "USD",
    "cik": "0000855654",
    "isin": "US45253H1014",
    "cusip": "45253H101",
    "exchange": "NASDAQ Global Select",
    "exchangeShortName": "NASDAQ",
    "industry": "Biotechnology",
    "website": "https://www.immunogen.com",
    "description": "ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.",
    "ceo": "Mr. Mark Joseph Enyedy",
    "sector": "Healthcare",
    "country": "US",
    "fullTimeEmployees": "277",
    "phone": "781 895 0600",
    "address": "830 Winter Street",
    "city": "Waltham",
    "state": "MA",
    "zip": "02451-1477",
    "dcfDiff": 2.80127,
    "dcf": 7.55127,
    "image": "https://financialmodelingprep.com/image-stock/IMGN.png",
    "ipoDate": "1989-11-17",
    "defaultImage": false,
    "isEtf": false,
    "isActivelyTrading": true,
    "isAdr": false,
    "isFund": false
  }
]